Biocon

#Biocon started FY27 on a steady footing, with the Biopharma business as the key growth driver. Strong performance across geographies and the successful integration of biosimilars and generics businesses, contributed to this momentum.

Q1 highlights:
➡️ Consolidated operating revenue increased 10% YoY to Rs 4,336 crore, driven by strong growth in the Biopharma business.

➡️ Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets.

➡️ Biosimilars revenue increased 16% YoY to Rs 2,855 crore.

➡️ Generics revenue increased 21% YoY Rs 760 crore.

Read more: biocon.com/biocon-q1fy27-…
#FY27Results #Q1FY27

Biocon continued to make good progress on its strategic priorities in Q2 and H1 FY27 driven by new business wins, regulatory approvals and new product launches across its Biopharma business.

Q2 highlights
• Consolidated operating revenue increased 2% YoY to Rs 4,389 crore.
• Biopharma revenue increased 5% YoY to Rs 3,583 crore.

H1 highlights
• Consolidated operating revenue increased 6% YoY to Rs 8,725 crore.
• Biopharma revenue increased 11% YoY to Rs 7,200 crore.
• Net profit increased by 57% YoY to Rs 182 crore.

Read more at f.mtr.cool/jofn8syu21

#Q2FY27 #H1FY27

Expansion of access begins with simple conversations.

Starting tomorrow, from 6–8 October, the Biocon team will be on the ground at Fiera Milano, ready to discuss our established capabilities in biosimilars, complex APIs, and global-scale manufacturing.

If you are looking for a reliable, long-term execution partner to help navigate the future of healthcare, we invite you to visit us.

Meet us at Stand 7D34 to explore how our capabilities and global scale can support your ambitions. Let’s have a conversation.

#Biocon #CPHIMilan2026 #PharmaManufacturing #Biosimilars #PatientAccess #GlobalScale #HealthcarePartnerships

“CPHI Worldwide is where the global pharmaceutical industry converges to showcase innovation, foster collaboration, and shape the future of healthcare.
For Biocon, it is an opportunity to showcase the science, scale and quality that underpin our mission to expand access to high-quality, affordable medicines worldwide.

From translating innovation into real-world impact to delivering consistently for patients, healthcare systems and partners across markets, our work is guided by a clear purpose: making healthcare more accessible to those who need it most.
Realizing this requires meaningful partnerships that bring together complementary strengths, accelerate access to medicines, and extend the reach of innovation to underserved populations around the world.

At CPHI Milan 2026, we look forward to strengthening existing collaborations, building new relationships, and exploring opportunities that create shared value while advancing patient access globally.
If you're attending CPHI Milan, we invite you to meet Team Biocon and discover how, together, we can turn scientific progress into meaningful healthcare impact.”
Deepali Naair (Global Head of Brand, Marketing & Corporate Communications)

#Biocon #CPHIMilan2026 #HealthcareInnovation #GlobalPartnerships #PatientAccess #Pharmaceuticals #Biologics #Biosimilars #GlobalHealth #CPHI

“CPHI Milan brings together the global pharmaceutical community to exchange perspectives, strengthen collaborations and explore opportunities for long-term growth.

For API customers, a sourcing decision extends beyond the molecule itself. It demands a partner capable of consistently aligning quality, cost and reliable delivery across markets and over the long term.

Biocon’s API business is built to support these priorities through a broad portfolio, established regulatory credentials, proven manufacturing capability, and a sustained commitment to customer requirements.

Today, the business spans more than 45 active APIs and is supported by 68 US Drug Master Files and 29 Certificates of Suitability. Its capabilities extend from fermentation-based statins and immunosuppressants to oncology high-potency APIs and GLP-1 peptides, with every programme underpinned by a commitment to customers’ launch plans.

If you're attending CPHI Milan, we invite you to meet Team Biocon.

Let’s explore opportunities for enduring collaboration.”
- Amit Kaptain (Head – Global API Commercials & FDF – EM)

#CPHI2026 #CPHIMilan #TeamBiocon #BioconAPI #PharmaceuticalIndustry #ActivePharmaceuticalIngredients #APIs #GlobalPharma